ERBB2 and neoplasm: [21] Other selected HER2-directed therapies,[22] including trastuzumab emtansine (T-DM1), pertuzumab, and lapatinib, have not shown clinical benefit in HER2+ AGC patients despite their success in treating other tumor types.[23]